Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

STEVEN P HERZOG

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1972579449
CMS profile
271142
Location
DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$95,740.67

217 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

By paying entity

PY2020 · entire year · sorted by reported total

Page 4 of 5; records 151–200 of 217 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

STEVEN P HERZOG

NPI 1972579449 · CMS profile ID 271142

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 5; records 151–200 of 217 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1972579449?year=2020&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
STEVEN P HERZOG, NPI 1972579449, CMS profile ID 271142. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 217 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1972579449?year=2020&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). STEVEN P HERZOG, NPI 1972579449, CMS profile ID 271142. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 217 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1972579449?year=2020&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
STEVEN P HERZOG, NPI 1972579449, CMS profile ID 271142, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 5; records 151–200 of 217 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1972579449?year=2020&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

217 matching records · $95,740.67 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 217 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–200 of 217.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Sunovion Pharmaceuticals Inc. $16.9504/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748590817 CMS
Amgen Inc. $27.1604/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741322501 CMS
Allergan, Inc. $500.0004/08/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723732719 CMS
Allergan, Inc. $500.0004/07/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723732717 CMS
Allergan, Inc. $9.6304/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723732715 CMS
Upsher-Smith Laboratories LLC $13.0403/31/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 733048083 CMS
Genentech USA, Inc. $18.6903/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743114413 CMS
Allergan, Inc. $9.6303/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723732713 CMS
Sunovion Pharmaceuticals Inc. $16.7403/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748590815 CMS
Assertio Therapeutics, Inc. $16.7403/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748831597 CMS
Biogen, Inc. $17.0903/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737283765 CMS
Amgen Inc. $8.1403/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741322499 CMS
Supernus Pharmaceuticals, Inc. $11.5503/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748338943 CMS
Sunovion Pharmaceuticals Inc. $20.0602/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748590823 CMS
Teva Pharmaceuticals USA, Inc. $4.7602/26/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749481907 CMS
Allergan, Inc. $8.2102/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723732711 CMS
Genentech USA, Inc. $20.0402/19/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743114405 CMS
Grifols USA, LLC $17.7702/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 750422211 CMS
MERZ NORTH AMERICA, INC. $32.5702/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737048031 CMS
Allergan, Inc. $7.1302/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723732709 CMS
Allergan, Inc. $9.0802/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723732703 CMS
Allergan, Inc. $3,000.0002/06/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723732705 CMS
Allergan, Inc. $105.2802/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723732707 CMS
Upsher-Smith Laboratories LLC $5.2702/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 733041013 CMS
Allergan, Inc. $129.3202/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723732699 CMS
Allergan, Inc. $3,000.0002/04/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723732701 CMS
Novartis Pharmaceuticals Corporation $5.5302/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725802701 CMS
Allergan, Inc. $2,400.0001/30/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723732681 CMS
Allergan, Inc. $10.5101/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723732683 CMS
Allergan, Inc. $10.2901/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723732685 CMS
Allergan, Inc. $0.6301/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723732687 CMS
Allergan, Inc. $4,200.0001/30/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723732689 CMS
Allergan, Inc. $418.1901/30/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723732691 CMS
Allergan, Inc. $2,400.0001/30/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723732693 CMS
Allergan, Inc. $344.0501/30/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723732695 CMS
Allergan, Inc. $125.0001/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723732697 CMS
Teva Pharmaceuticals USA, Inc. $4.7601/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749463769 CMS
Sunovion Pharmaceuticals Inc. $20.3201/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748590825 CMS
Amneal Pharmaceuticals LLC $20.1601/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719983475 CMS
Allergan, Inc. $46.0001/25/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723732669 CMS
Allergan, Inc. $40.2101/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723732671 CMS
Allergan, Inc. $150.9201/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723732673 CMS
Allergan, Inc. $20.0001/25/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723732675 CMS
Allergan, Inc. $4,500.0001/25/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723732677 CMS
Allergan, Inc. $50.2401/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723732679 CMS
Allergan, Inc. $149.9801/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723732665 CMS
Allergan, Inc. $124.4201/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723732667 CMS
Allergan, Inc. $19.7601/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723732663 CMS
Teva Pharmaceuticals USA, Inc. $6.2501/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749515499 CMS
Novartis Pharmaceuticals Corporation $5.9201/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725802695 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $32,301.68 111
PY2020 $95,740.67 217
PY2021 $128,417.43 236
PY2022 $73,468.07 193
PY2023 $36,934.52 105
PY2024 $70,476.29 147
PY2025 $23,492.76 83

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $142,733.43 74
PY2024 Principal investigator $39,317.11 24
PY2023 Principal investigator $64,238.33 18
PY2022 Recipient $510.00 1
PY2022 Principal investigator $57,466.98 23
PY2021 Recipient $1,065.99 1
PY2021 Principal investigator $51,200.10 17
PY2020 Principal investigator $24,433.66 8
PY2019 Principal investigator $41,652.43 14

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

74 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,854.00 12/31/2025 Non-covered Recipient Entity
TEXAS NEUROLOGY PA
A Phase 3 Multicenter 24-Week Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Atogepant When Added to OnabotulinumtoxinA (BOTOX) for the Preventive Treatment of Chronic Migraine No dispute reported 06/30/2026 1202532805
Principal investigator 1 ABBVIE INC. $550.00 12/31/2025 Non-covered Recipient Entity
TEXAS NEUROLOGY PA
A Phase 3, Multicenter, Open-Label 156-Week Extension Study To Evaluate The Long-Term Safety And Tolerability Of Oral Atogepant For The Prevention Of Migraine In Participants With Chronic Or Episodic Migraine No dispute reported 06/30/2026 1202532807
Principal investigator 1 Ipsen Innovation $1,465.06 12/24/2025 Non-covered Recipient Entity
Texas Neurology
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288224
Principal investigator 1 Ipsen Innovation $2,394.97 12/24/2025 Non-covered Recipient Entity
Texas Neurology
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288226
Principal investigator 1 Ipsen Innovation $150.00 12/22/2025 Non-covered Recipient Entity
Texas Neurology
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288534
Principal investigator 1 ABBVIE INC. $1,000.00 12/18/2025 Non-covered Recipient Entity
TEXAS NEUROLOGY PA
Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine No dispute reported 06/30/2026 1202531092
Principal investigator 1 ABBVIE INC. $2,000.00 12/04/2025 Non-covered Recipient Entity
TEXAS NEUROLOGY PA
Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine No dispute reported 06/30/2026 1202526466
Principal investigator 1 H. Lundbeck A S $3,877.00 12/01/2025 Non-covered Recipient Entity
TEXAS NEUROLOGY PA
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251777883
Principal investigator 1 H. Lundbeck A S $892.00 12/01/2025 Non-covered Recipient Entity
TEXAS NEUROLOGY PA
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251777886
Principal investigator 1 H. Lundbeck A S $1,751.00 12/01/2025 Non-covered Recipient Entity
TEXAS NEUROLOGY PA
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251777891
Principal investigator 1 H. Lundbeck A S $647.00 12/01/2025 Non-covered Recipient Entity
TEXAS NEUROLOGY PA
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251777894
Principal investigator 1 H. Lundbeck A S $2,076.00 12/01/2025 Non-covered Recipient Entity
TEXAS NEUROLOGY PA
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251777899
Principal investigator 1 Ipsen Innovation $1,659.66 10/27/2025 Non-covered Recipient Entity
Texas Neurology
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288220
Principal investigator 1 Ipsen Innovation $1,465.06 10/27/2025 Non-covered Recipient Entity
Texas Neurology
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288222
Principal investigator 1 H. Lundbeck A S $3,877.00 10/15/2025 Non-covered Recipient Entity
TEXAS NEUROLOGY PA
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251775681
Principal investigator 1 H. Lundbeck A S $647.00 10/15/2025 Non-covered Recipient Entity
TEXAS NEUROLOGY PA
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251775685
Principal investigator 1 H. Lundbeck A S $2,076.00 10/15/2025 Non-covered Recipient Entity
TEXAS NEUROLOGY PA
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251775689
Principal investigator 1 Ipsen Innovation $150.00 10/10/2025 Non-covered Recipient Entity
Texas Neurology
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288532
Principal investigator 1 ABBVIE INC. $12,748.14 10/07/2025 Non-covered Recipient Entity
TEXAS NEUROLOGY PA
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 1202513419
Principal investigator 1 H. Lundbeck A S $3,877.00 09/10/2025 Non-covered Recipient Entity
TEXAS NEUROLOGY PA
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251774485
Principal investigator 1 H. Lundbeck A S $647.00 09/10/2025 Non-covered Recipient Entity
TEXAS NEUROLOGY PA
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251774489
Principal investigator 1 H. Lundbeck A S $2,048.00 09/10/2025 Non-covered Recipient Entity
TEXAS NEUROLOGY PA
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251774493
Principal investigator 1 H. Lundbeck A S $2,076.00 09/10/2025 Non-covered Recipient Entity
TEXAS NEUROLOGY PA
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251774498
Principal investigator 1 Ipsen Innovation $3,506.97 08/28/2025 Non-covered Recipient Entity
Texas Neurology
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288214
Principal investigator 1 Ipsen Innovation $1,465.06 08/28/2025 Non-covered Recipient Entity
Texas Neurology
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288216
Principal investigator 1 Ipsen Innovation $4,432.71 08/28/2025 Non-covered Recipient Entity
Texas Neurology
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288218
Principal investigator 1 H. Lundbeck A S $3,877.00 08/07/2025 Non-covered Recipient Entity
TEXAS NEUROLOGY PA
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251773364
Principal investigator 1 H. Lundbeck A S $1,751.00 08/07/2025 Non-covered Recipient Entity
TEXAS NEUROLOGY PA
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251773368
Principal investigator 1 H. Lundbeck A S $2,048.00 08/07/2025 Non-covered Recipient Entity
TEXAS NEUROLOGY PA
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251773371
Principal investigator 1 Ipsen Innovation $150.00 07/31/2025 Non-covered Recipient Entity
Texas Neurology
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288530
Principal investigator 1 Ipsen Innovation $3,000.00 07/17/2025 Non-covered Recipient Entity
Texas Neurology
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288204
Principal investigator 1 Ipsen Innovation $2,600.00 07/17/2025 Non-covered Recipient Entity
Texas Neurology
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288206
Principal investigator 1 Ipsen Innovation $7,200.00 07/17/2025 Non-covered Recipient Entity
Texas Neurology
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288208
Principal investigator 1 H. Lundbeck A S $3,877.00 07/09/2025 Non-covered Recipient Entity
TEXAS NEUROLOGY PA
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251771935
Principal investigator 1 H. Lundbeck A S $647.00 07/09/2025 Non-covered Recipient Entity
TEXAS NEUROLOGY PA
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251771939
Principal investigator 1 H. Lundbeck A S $2,076.00 07/09/2025 Non-covered Recipient Entity
TEXAS NEUROLOGY PA
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251771942
Principal investigator 1 Ipsen Innovation $7,200.00 07/09/2025 Non-covered Recipient Entity
Texas Neurology
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288202
Principal investigator 1 Ipsen Innovation $3,000.00 07/09/2025 Non-covered Recipient Entity
Texas Neurology
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288210
Principal investigator 1 Ipsen Innovation $2,600.00 07/09/2025 Non-covered Recipient Entity
Texas Neurology
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288212
Principal investigator 1 Ipsen Innovation $207.11 06/30/2025 Non-covered Recipient Entity
Texas Neurology
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288200
Principal investigator 1 Ipsen Innovation $270.00 06/25/2025 Non-covered Recipient Entity
Texas Neurology
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288524
Principal investigator 1 Ipsen Innovation $450.00 06/25/2025 Non-covered Recipient Entity
Texas Neurology
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288526
Principal investigator 1 Ipsen Innovation $300.00 06/25/2025 Non-covered Recipient Entity
Texas Neurology
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288528
Principal investigator 1 H. Lundbeck A S $3,877.00 06/06/2025 Non-covered Recipient Entity
TEXAS NEUROLOGY PA
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251771079
Principal investigator 1 H. Lundbeck A S $647.00 06/06/2025 Non-covered Recipient Entity
TEXAS NEUROLOGY PA
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251771083
Principal investigator 1 H. Lundbeck A S $2,076.00 06/06/2025 Non-covered Recipient Entity
TEXAS NEUROLOGY PA
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251771087
Principal investigator 1 Ipsen Innovation $482.00 05/13/2025 Non-covered Recipient Entity
Texas Neurology
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288522
Principal investigator 1 H. Lundbeck A S $3,877.00 05/07/2025 Non-covered Recipient Entity
TEXAS NEUROLOGY PA
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251770061
Principal investigator 1 H. Lundbeck A S $2,048.00 05/07/2025 Non-covered Recipient Entity
TEXAS NEUROLOGY PA
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251770065
Principal investigator 1 ABBVIE INC. $503.25 05/06/2025 Non-covered Recipient Entity
TEXAS NEUROLOGY PA
Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine No dispute reported 06/30/2026 1202481889
Principal investigator 1 Ipsen Innovation $207.11 04/28/2025 Non-covered Recipient Entity
Texas Neurology
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288194
Principal investigator 1 Ipsen Innovation $207.11 04/28/2025 Non-covered Recipient Entity
Texas Neurology
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288196
Principal investigator 1 Ipsen Innovation $207.11 04/28/2025 Non-covered Recipient Entity
Texas Neurology
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288198
Principal investigator 1 Ipsen Innovation $450.00 04/25/2025 Non-covered Recipient Entity
Texas Neurology
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288518
Principal investigator 1 Ipsen Innovation $270.00 04/25/2025 Non-covered Recipient Entity
Texas Neurology
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288520
Principal investigator 1 H. Lundbeck A S $3,877.00 04/09/2025 Non-covered Recipient Entity
TEXAS NEUROLOGY PA
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251769550
Principal investigator 1 H. Lundbeck A S $2,076.00 04/09/2025 Non-covered Recipient Entity
TEXAS NEUROLOGY PA
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251769553
Principal investigator 1 H. Lundbeck A S $647.00 04/09/2025 Non-covered Recipient Entity
TEXAS NEUROLOGY PA
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251769556
Principal investigator 1 H. Lundbeck A S $500.00 04/02/2025 Non-covered Recipient Entity
TEXAS NEUROLOGY PA
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251769394
Principal investigator 1 H. Lundbeck A S $2,599.00 04/02/2025 Non-covered Recipient Entity
TEXAS NEUROLOGY PA
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251769399
Principal investigator 1 H. Lundbeck A S $10,000.00 04/02/2025 Non-covered Recipient Entity
TEXAS NEUROLOGY PA
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251769420
Principal investigator 1 H. Lundbeck A S $130.00 04/02/2025 Non-covered Recipient Entity
TEXAS NEUROLOGY PA
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251769425
Principal investigator 1 ABBVIE INC. $2,600.00 03/06/2025 Non-covered Recipient Entity
TEXAS NEUROLOGY PA
A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine No dispute reported 06/30/2026 1202457319
Principal investigator 1 Ipsen Innovation $150.00 03/06/2025 Non-covered Recipient Entity
Texas Neurology
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288512
Principal investigator 1 Ipsen Innovation $90.00 03/06/2025 Non-covered Recipient Entity
Texas Neurology
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288514
Principal investigator 1 Ipsen Innovation $150.00 03/06/2025 Non-covered Recipient Entity
Texas Neurology
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288516
Principal investigator 1 Ipsen Innovation $300.00 02/06/2025 Non-covered Recipient Entity
Texas Neurology
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288506
Principal investigator 1 Ipsen Innovation $180.00 02/06/2025 Non-covered Recipient Entity
Texas Neurology
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288508
Principal investigator 1 Ipsen Innovation $300.00 02/06/2025 Non-covered Recipient Entity
Texas Neurology
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184288510
Principal investigator 1 ABBVIE INC. $3,100.00 02/05/2025 Non-covered Recipient Entity
TEXAS NEUROLOGY PA
A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine No dispute reported 06/30/2026 1202446090
Principal investigator 1 Ipsen Innovation $207.11 01/31/2025 Non-covered Recipient Entity
Texas Neurology
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288192
Principal investigator 1 Ipsen Innovation $90.00 01/13/2025 Non-covered Recipient Entity
Texas Neurology
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288500
Principal investigator 1 Ipsen Innovation $150.00 01/13/2025 Non-covered Recipient Entity
Texas Neurology
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288502
Principal investigator 1 Ipsen Innovation $150.00 01/13/2025 Non-covered Recipient Entity
Texas Neurology
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184288504

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2025 Amount invested $175,647.75 1
PY2025 Value of interest $468,226.12 1
PY2024 Amount invested $119,967.48 1
PY2024 Value of interest $292,578.38 1
PY2023 Amount invested $61,977.68 1
PY2023 Value of interest $172,610.89 1
PY2022 Amount invested $59,149.52 1
PY2022 Value of interest $110,633.21 1
PY2021 Amount invested $23,609.84 1
PY2021 Value of interest $51,483.69 1
PY2020 Amount invested $18,368.47 1
PY2020 Value of interest $27,873.85 1
PY2019 Amount invested $9,126.39 1
PY2019 Value of interest $9,505.38 1

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

7 records · PY2019–2025

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2025 NEUROLOGY PRACTICE CONSORTIUM GPO, LLC $175,647.75 $468,226.12 Payments are made to a group practice and split evenly among physician partners by ownership percentage. The group practice owns 40% of the GPO. Value of interest is a cumulative total calculated by adding year-over-year ownership values per provider. Physician Covered Recipient No dispute reported 06/30/2026 1246451117
PY2024 NEUROLOGY PRACTICE CONSORTIUM GPO, LLC $119,967.48 $292,578.38 1.) Value of interest is a cumulative total calculated by adding year-over-year ownership values per provider. 2.) Payments are made to a group practice and then split evenly among physician partners. The group practice owns 40% of the GPO. Physician Covered Recipient No dispute reported 06/30/2026 1087691579
PY2023 NEUROLOGY PRACTICE CONSORTIUM GPO, LLC $61,977.68 $172,610.89 1.) Value of interest is a cumulative total calculated by adding year-over-year ownership values per provider. 2.) Payments are made to a group practice and then split evenly among physician partners. The group practice owns 40% of the GPO. Physician Covered Recipient No dispute reported 06/30/2026 1056884221
PY2022 NEUROLOGY PRACTICE CONSORTIUM GPO, LLC $59,149.52 $110,633.21 The organization the physician practices at owns 40% of the GPO, therefore 40% of the GPO profit is split among the physician partners. Physician Covered Recipient No dispute reported 06/30/2026 961677623
PY2021 NEUROLOGY PRACTICE CONSORTIUM GPO, LLC $23,609.84 $51,483.69 The organization the physician practices at owns 40% of the GPO, therefore 40% of the GPO profit is split among the physician partners. Physician Covered Recipient No dispute reported 06/30/2026 851048743
PY2020 NEUROLOGY PRACTICE CONSORTIUM GPO, LLC $18,368.47 $27,873.85 Physician is employed at outpatient neurology practice that owns a percentage of the GPO Physician Covered Recipient No dispute reported 06/30/2026 753245825
PY2019 NEUROLOGY PRACTICE CONSORTIUM GPO, LLC $9,126.39 $9,505.38 Physician is employed at outpatient neurology practice that owns a percentage of the GPO Physician Covered Recipient No dispute reported 06/30/2026 708351973